ABCA1 p.Gly1201Ala
| Predicted by SNAP2: | A: N (57%), C: D (63%), D: D (80%), E: D (75%), F: D (66%), H: D (59%), I: D (75%), K: D (85%), L: D (80%), M: D (63%), N: D (71%), P: N (57%), Q: D (71%), R: D (53%), S: N (61%), T: D (75%), V: D (75%), W: D (85%), Y: D (75%), |
| Predicted by PROVEAN: | A: D, C: D, D: D, E: D, F: D, H: D, I: D, K: D, L: D, M: D, N: D, P: D, Q: D, R: D, S: D, T: D, V: D, W: D, Y: D, |
[switch to compact view]
Comments [show]
None has been submitted yet.
[hide] Transporters and drug therapy: implications for dr... Clin Pharmacol Ther. 2005 Sep;78(3):260-77. Ho RH, Kim RB
Transporters and drug therapy: implications for drug disposition and disease.
Clin Pharmacol Ther. 2005 Sep;78(3):260-77., [PMID:16153397]
Abstract [show]
The efficacy of drug therapy results from the complex interplay of multiple processes that govern drug disposition and response. Most studies to date have focused on the contribution of drug-metabolizing enzymes to the drug disposition process. However, over the past decade, it has become increasingly apparent that carrier-mediated processes, or transporters, also play critical roles in the overall disposition of numerous drugs in clinical use. In addition to their roles in xenobiotic transport, drug transporters often mediate important physiologic functions via transport of endogenous substrates such as amino acids, bile acids, and hormones that are critical for maintenance of normal homeostasis. In this review we focus on the emerging field of transporter proteins in relation to the drug disposition process, with particular emphasis on clinical implications of transporters to drug-drug interactions and subsequent development of adverse effects, interindividual variability in drug response, and human disease.
Comments [show]
None has been submitted yet.
No. Sentence Comment
102 Genetic polymorphisms in drug transporters Gene symbol Transporter Polymorphism Allele frequency Potential effects References ABCB1 MDR1 C3435T 54% White Susceptibility to renal tumors 65 26% Black Susceptibility to ulcerative colitis 67 53% Asian American Susceptibility to Parkinson`s disease 66 Response in refractory epilepsy 68 Overall survival in acute myeloid leukemia 135 CD4 response in HIV-1 therapy 69 Susceptibility to childhood acute lymphoblastic leukemia 136 Increased cyclosporine clearance in renal transplant patients 137 Smaller reduction in low-density lipoprotein cholesterol in response to atorvastatin treatment 138 MDR1 G2677T 46% White Lower fexofenadine plasma levels 139 6.5% Black Healthy volunteers Reduced risk of chronic renal dysfunction with calcineurin inhibitors after liver transplantation 140 Susceptibility to inflammatory bowel disease 141 ABCA1 ABCA1 G655A 25% White Decreased triglyceride levels, increased high-density lipoprotein plasma levels, decreased risk of atherosclerosis 118 A5397C Rare Low levels of high-density lipoprotein cholesterol 124, 125 ABCG2 BCRP C421A 46% Japanese Decreased protein expression and increased sensitivity to irinotecan (SN-38), mitoxantrone, and topotecan in vitro 142 14% White Increased plasma levels of diflomotecan in adult cancer patients 143 SLC22A1 OCT1 C181T 7.2% White Decreased uptake of MPP in vitro 76 5.6% Hispanic T262C 0.6% White Decreased uptake of MPP in vitro 77 Decreased uptake of serotonin in vitro C1022T 8.2% Black Decreased uptake of MPP in vitro 76 11.7% Asian American G1201A 3.2% White Decreased uptake of serotonin in vitro 76, 77 Decreased uptake of MPP in vitro G1393A 4% White Decreased uptake of MPP in vitro 76 SLC22A2 OCT2 G495A 1% Black Decreased uptake of MPP in vitro 144 C1198T 1.5% Black Decreased uptake of MPP in vitro 144 SLCO1B1 OATP1B1 T521C 14% White Increased pravastatin plasma levels 79, 145, 146 16% Japanese Decreased steroid conjugate uptake in vitro 78 G1463C 9% Black Decreased steroid conjugate uptake in vitro 78 SLCO1B3 OATP1B3 G1564T 1.9% White Impaired protein trafficking to membrane, decreased bile acid transport in vitro 147 SLCO2B1 OATP2B1 C1457T 30.9% Japanese Decreased transport estrone sulfate in vitro 80 MPP, 1-Methyl-4-phenylpyridinium.
X
ABCA1 p.Gly1201Ala 16153397:102:1573
status: NEW